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Abstract: We aimed to assess protein expressions of p16 and pRB in breast cancer and explore the clinicopathologic 
implications. Tissue microarray (TMA) was constructed with 406 cases of breast cancer. The cases were subgrouped 
into luminal A, luminal B, HER-2, and triple negative breast cancer (TNBC) based on the results of immunohisto-
chemical stains for ER, PR, HER-2, and Ki-67 and fluorescent in situ hybridization (FISH) for HER-2. One hundred 
and sixty-eight cases were allocated to the subgroup luminal A; 87 cases to the luminal B; 32 cases to the HER-2; 
and 119 cases to the TNBC. The TNBC group showed the highest negative rate for p16, and the luminal B and HER-2 
groups showed the highest positive rate for p16 (P < 0.001). Alteration of p16 was the highest in the luminal B and 
HER-2 groups, and pRB expression rate was the highest in the HER-2 group and lowest in the luminal A group. In 
addition, p16(+)/pRB(+) type was the most common in the luminal B group, p16(+)/pRB(-) in the luminal A group, 
and p16(-)/pRB(+) in the TNBC group (P < 0.001). Altered p16/pRB(+) and non-altered p16/pRB(+) type was the 
most common in the luminal B, and altered p16/pRB(-) and non-altered p16/pRB(+) type was the most common in 
the luminal A (P < 0.001). Alteration of p16 was correlated with higher Ki67 labeling index (LI) (P = 0.013), and p16 
negativity was correlated with ER negativity (P = 0.002), PR negativity (P = 0.004), and higher Ki67 LI (P < 0.001). 
pRB positivity was correlated with PR negativity (P = 0.009), HER-2 positivity (P = 0.001), and higher Ki-67 LI (P 
< 0.001). In luminal group A, p16 alteration was correlated with shorter DFS in univariate analysis (P = 0.024). In 
conclusion, Expression rates of p16 and pRB differ according to the molecular subgroups of breast cancer and they 
subsequently correlate with clnicopathologic factors. 
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Introduction 
Unrestricted cellular proliferation due to dereg-
ulation of cell cycle is the key feature of malig-
nancy, and an alteration in the cell cycle check 
points is one of the most common abnormali-
ties encountered in the molecular basis of 
human cancer. Among these cell cycle check 
points are p16 and pRB, the former a cyclin 
dependent kinase 2 (CDKN2) gene products [1] 
serving as a negative regulator of cell cycle and 
the latter an important regulator of cell cycle 
repressing progression from G1 phase to S 
phase [2]. Phosphorylation by cyclin D makes 
pRB inactive, thus igniting the start of cell cycle. 
On the other hand, p16 suppresses cyclin D 
activity by bonding with cyclin-dependent kin- 
ase 4 and 6, slowing down the cell replication 
rate by allowing pRB to stay in its dephosphory-
lated, active status [3]. Because p16 and pRB 
have such an essential role in cell proliferation, 
altered expressions of p16 and pRB and their 
correlation with clinicopathologic factors have 
been reported in various types of human can-
cer [4-8]. However, reports on their altered 
expressions in breast cancer and their subse-
quent clinicopathologic implications are limited 
in number [9-14]. We investigated their differ-
ential expression patterns in breast cancer 
according to the molecular subtypes and ex- 
plored the clinicopathologic significance.
Materials and methods
Patient selection and histologic evaluation
Patients who underwent surgical excision of 
invasive ductal carcinoma, NOS, from January 
2000 to December 2006 in Yonsei University 
Severance Hospital were subject to the study. 
Patients who received preoperative chemother-
apy or hormonal therapy were excluded. This 
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study was approved by the Institutional Review 
Board of Yonsei University Severance Hospital, 
and was exempt from informed consent of the 
patients. Hematoxylin and Eosin (H&E) stained 
slides of all cases were reviewed by a breast 
pathologist (Koo, JS). Histological grade was 
assessed using the Nottingham grading sys-
tem [15]. Clinicopathologic parameters evalu-
ated in each case included patient age at initi- 
al diagnosis, lymph node metastasis, tumor 
recurrence, distant metastasis, and patient sur- 
vival. 
Tissue microarray
On H&E-stained slides of tumors, a representa-
tive area was selected and a corresponding 
spot was marked on the surface of the paraffin 
block. Using a biopsy needle, the selected area 
was punched out and a 3-mm tissue core was 
placed into a 6 × 5 recipient block. Tissue of 
invasive tumor was extracted. More than 2 tis-
sue cores were extracted to minimize extrac-
tion bias. Each tissue core was assigned with a 
unique tissue microarray location number that 
was linked to a database containing other clini-
copathologic data. 
Immunohistochemistry 
All immunohistochemistry was performed with 
formalin-fixed, paraffin-embedded tissue sec-
tions. Briefly, 5-μm-thick sections were obtained 
with a microtome, transferred onto adhesive 
slides, and dried at 62°C for 30 minutes. After 
incubation with primary antibodies, immunode-
tection was performed with biotinylated anti-
mouse immunoglobulin, followed by peroxi-
dase-labeled streptavidin using a labeled stre- 
ptavidin biotin kit with 3,3’-diaminobenzidine 
chromogen as the substrate. The primary anti-
body incubation step was omitted in the nega-
tive control. Positive control tissue was used 
as per the manufacturer’s recommendation. 
Slides were counterstained with Harris hema- 
toxylin.
Interpretation of immunohistochemical stain-
ing
All immunohistochemical markers were acce- 
ssed by light microscopy. A cut-off value of 1% 
or more positively stained nuclei was used to 
define ER and PR positivity [16]. HER-2 staining 
was analyzed according to the American Society 
of Clinical Oncology (ASCO)/College of American 
Pathologists (CAP) guidelines using the follow-
ing categories: 0 = no immunostaining; 1+ = 
weak incomplete membranous staining, less 
than 10% of tumor cells; 2+ = complete mem-
branous staining, either uniform or weak in at 
least 10% of tumor cells; and 3+ = uniform 
intense membranous staining in at least 30% 
of tumor cells [17]. HER-2 immunostaining was 
considered positive when strong (3+) membra-
nous staining was observed, whereas cases 
with 0 to 1+ were regarded as negative. Cases 
showing 2+ HER-2 expression were evaluated 
for HER-2 amplification by fluorescent in situ 
hybridization (FISH).
Immunohistochemical stains for p16 and pRB 
were assessed semi-quantitatively under the 
light microscopy according to the previously 
reported method [18]. Staining results in tumor 
and stromal cells were assessed as 0: negative 
or immunostaining in < 10% of the tumor, 1: 
expression in 11-25% of the tumor, 2: positive 
in 26%-50% of the tumor, 3: positive in 51%-
75% of the tumor, and 4: positive in 76%-100% 
of the tumor. For p16, grade 1 and 2 were con-
sidered low positive, 3 and 4 high positive, and 
grade 1 and 4 were considered as altered 
expression [19]. For pRB, grade 1 or higher was 
considered positive. 
Tumor phenotype classification
In this study, we classified breast cancer phe-
notypes according to the immunohistochemis-
try results for ER, PR, HER-2, Ki-67 and FISH 
results for HER-2 as follows [20]: luminal A 
type, ER or/and PR positive, HER-2 negative 
and Ki-67 LI < 14%; Luminal B type, (HER-2 
negative) ER or/and PR positive, HER-2 nega-
tive and Ki-67 LI ≥ 14%; (HER-2 positive) ER or/
and PR positive and HER-2 overexpressed or/
and amplified; HER-2 overexpression type, ER 
and PR negative and HER-2 overexpressed or/
and amplified; TNBC type: ER, PR, and HER-2 
negative. 
Statistical analysis
Data were analyzed using SPSS for Windows, 
Version 12.0 (SPSS Inc., Chicago, IL, USA). For 
determination of statistical significance, Stu- 
dent’s t and Fisher’s exact tests were used for 
continuous and categorical variables, respec-
tively. In the case of analyzing data with multi-
ple comparisons, a corrected p-value with the 
application of the Bonferroni multiple com- 
parison procedure was used. Statistical signifi-
cance was set to P < 0.05. Kaplan-Meier sur-
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vival curves and log-rank statistics were em- 
ployed to evaluate time to tumor recurrence 
and overall survival. Multivariate regression an- 
alysis was performed using the Cox proportion-
al hazards model.
Results
Basal characteristics of breast cancer 
The clinicopathologic features of breast cancer 
subject to this study are shown in Table 1. 
Among the total number of 406 cases, 168 
were luminal A, 87 were luminal B, 32 were 
HER-2, and 119 were TNBC. These molecular 
subtypes showed difference in histologic grade 
(P < 0.001), tumor stage (P = 0.022), and Ki67 
LI (P < 0.001): luminal A showed lower histo-
logic grade, less advanced tumor stage, and 
lower Ki67 LI; HER-2 and TNBC showed higher 
histologic grade, advanced tumor stage, and 
higher Ki67 LI (Table 2).
Expression of p16 and pRB according to the 
molecular subtypes
For each molecular subtype of breast cancer, 
p16 expression (P < 0.001), p16 alteration sta-
tus (P = 0.018), and pRB expression (P < 0.001) 
were different. P16 negativity rate was higher 
in TNBC and high rate of p16 expression was 
more frequently observed in luminal B and 
HER-2. P16 alteration was higher in luminal B 
and HER-2 groups, and pRB expression was 
higher in HER-2 group and lower in luminal B 
group (Table 3 and Figure 1). 
The combined status of p16 and pRB expres-
sions was different according to the molecular 
subtypes (P < 0.001). P16(+)/pRB(+) was high-
er in luminal B, p16(+)/pRB(-) was higher in 
luminal A, p16(-)/pRB(+) and p16(-)/pRB(-) were 
Correlation between p16 and pRB expressions 
and clinicopathologic factors
Assessment of correlation between p16 and 
pRB expressions and clinicopathologic factors 
revealed correlation of p16 alteration with high-
er Ki67 LI (P = 0.013), and p16 negativity with 
ER negativity (P = 0.002), PR negativity (P = 
0.004), and higher Ki67 LI (P < 0.001). pRB 
positivity was correlated with PR negativity (P = 
0.009), HER-2 positivity (P = 0.001), and higher 
Ki67 LI (P < 0.001) (Table 5). 
When the combined status of p16 and pRB 
expressions was correlated with clinicopatho-
logic factors, p16/pRB type showed correlation 
with histologic grade (P = 0.029), ER status (P = 
0.001), HER-2 status (P = 0.003), and Ki67 LI 
(P < 0.001). On the other hand, p16(+)/pRB(-) 
type showed  lower histologic grade, ER positiv-
ity, PR positivity, HER-2 negativity, and lower 
Ki67 LI. P16(+)/pRB(+) type and p16(-)/pRB(-) 
type showed higher histologic grade, ER nega-
tivity, PR negativity, HER-2 positivity, and higher 
Ki67 LI. The combined status of p16 alteration 
and pRB expression was correlated with HER-2 
status (P = 0.007) and Ki67 LI (P < 0.001); 
altered p16/pRB(+) type and non-altered p16/
pRB(+) type showed higher HER-2 positivity and 
higher Ki67 LI; altered p16/pRB(-) and non-
altered p16/pRB(-) type was higher in HER-2 
negativity and lower Ki67 LI (Figure 2). 
Impact of p16 and pRB status on breast can-
cer prognosis
Expressions of p16 and pRB did not have sta-
tistically significant impact on the breast can-
cer prognosis in univariate analysis (Table 6). 
However, in the molecular subtype analysis, 
p16 alteration correlated with shorter DFS in 
the luminal A type (P = 0.024, Figure 3). 
Table 1. Source, clone, and dilution of used antibodies
Antibody Clone Dilution Company
Molecular subtype related
    ER SP1 1:100 Thermo Scientific, CA, USA
    PR PgR 1:50 DAKO, Denmark
    HER-2 Polyclonal 1:1500 DAKO, Denmark
    Ki-67 MIB-1 1:1000 Abcam, Cambridge, UK
Cell cycle related 
    p16 2D9A12 1:200 Abcam, Cambridge, UK
    Phospho pRB (S780) Polyclonal 1:100 Abcam, Cambridge, UK
higher in TNBC. The com-
bined status of p16 altera- 
tion and pRB expression was 
also different according to 
the molecular subtypes (P < 
0.001). Altered p16/pRB(+) 
and non-altered p16/pRB(+) 
types were higher in luminal 
B and altered p16/pRB(-) and 
non-altered p16/pRB(-) types 
were higher in luminal A 
(Table 4). 
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Discussion 
Our assessment of p16 and pRB expressions in 
breast cancer showed correlation between pRB 
positivity and PR negativity (P = 0.009), HER-2 
positivity (P = 0.001), and higher Ki67 LI (P < 
0.001), in contrast to the previous study show-
ing pRB negativity correlating with ER negativity 
Table 2. Clinicopathologic characteristics of patients according to breast cancer phenotype
Parameter Total (n = 406) (%)
Luminal A
(n = 168) (%)
Luminal B
(n = 87) (%)
HER-2
(n = 32) (%)
TNBC
(n = 119) (%) P-value
Age (years) 0.284
    ≤ 50 229 (56.4) 93 (55.4) 55 (63.2) 14 (43.8) 67 (56.3)
    > 50 177 (43.6) 75 (44.6) 32 (36.8) 18 (56.2) 52 (43.6)
Histologic grade < 0.001
    I/II 265 (65.3) 151 (89.9) 56 (64.4) 15 (46.9) 43 (36.1)
    III 141 (34.7) 17 (10.1) 31 (35.6) 17 (53.1) 76 (63.9)
Tumor stage 0.022
    T1 203 (50.0) 98 (58.3) 43 (49.4) 14 (43.8) 48 (40.3)
    T2/T3 203 (50.0) 70 (41.7) 44 (50.6) 18 (56.2) 71 (59.7)
Nodal metastasis 0.426
    Absent 250 (61.6) 101 (60.1) 49 (56.3) 20 (62.5) 80 (67.2)
    Present 156 (38.4) 67 (39.9) 38 (43.7) 12 (37.5) 39 (32.8)
Estrogen receptor status < 0.001
    Negative 156 (38.4) 2 (1.2) 3 (3.4) 32 (100.0) 119 (100.0)
    Positive 250 (61.6) 166 (98.8) 84 (96.6) 0 (0.0) 0 (0.0)
Progesterone receptor status < 0.001
    Negative 201 (49.5) 22 (13.1) 28 (32.2) 32 (100.0) 119 (100.0)
    Positive 205 (50.5) 146 (86.9) 59 (67.8) 0 (0.0) 0 (0.0)
HER-2 status < 0.001
    Negative 331 (81.5) 168 (100.0) 44 (50.6) 0 (0.0) 119 (100.0)
    Positive 75 (18.5) 0 (0.0) 43 (49.4) 32 (100.0) 0 (0.0)
Ki-67 LI (%) < 0.001
    ≤ 14 229 (56.4) 168 (100.0) 26 (29.9) 16 (50.0) 229 (56.4)
    > 14 177 (43.6) 0 (0.0) 61 (70.1) 16 (50.0) 177 (43.6)
Tumor recurrence 41 (10.1) 10 (6.0) 8 (9.2) 6 (18.8) 17 (14.3) 0.042
No. of patient deaths 43 (10.6) 10 (6.0) 9 (10.3) 7 (21.9) 17 (14.3) 0.020
TNBC, triple negative breast cancer.
Table 3. Expression of metabolism-related proteins according to breast cancer subtype
Parameter Total (n = 406) (%)
Luminal A
(n = 168) (%)
Luminal B
(n = 87) (%)
HER-2
(n = 32) (%)
TNBC
(n = 119) (%) P-value
p16 < 0.001
    Negative 31 (7.6) 3 (1.8) 9 (10.3) 1 (3.1) 18 (15.1)
    Low positive 212 (52.2) 102 (60.7) 37 (42.5) 18 (56.2) 55 (46.2)
    High positive 163 (40.1) 63 (37.5) 41 (47.1) 13 (40.6) 46 (38.7)
Alteration of p16 0.018
    No 212 (52.2) 102 (60.7) 37 (42.5) 18 (56.2) 55 (46.2)
    Yes 194 (47.8) 66 (39.3) 50 (57.5) 14 (43.8) 64 (53.8)
pRB < 0.001
    Negative 339 (83.5) 156 (92.9) 62 (71.3) 21 (65.6) 100 (84.0)
    Positive 67 (16.5) 12 (7.1) 25 (28.7) 11 (34.4) 19 (16.0)
TNBC, triple negative breast cancer.
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and higher histologic grade [10]. The latter 
used antibody for non-phosphorylated form of 
pRB, but we used antibody for phosphorylated 
form of pRB. Since non-phosphorylated form is 
an active form of pRB and phosphorylated form 
is an inactive form, the previous study and our 
current study identified active and inactive 
forms of pRB, respectively. Therefore, it is only 
natural that the previous study showed pRB 
negativity correlating with ER negativity and 
higher histologic grade, both related with 
aggressive behavior of breast cancer, and our 
study showed pRB positivity correlating with PR 
negativity, HER-2 positivity, and higher Ki67 LI, 
all three related with aggressive behavior of 
breast cancer. In other words, pRB positivity 
represents pRB alteration in this study. P16 
negativity was correlated with ER negativity (P 
= 0.002), PR negativity (P = 0.004), and higher 
Ki67 LI (P < 0.001). p16 normally abdicates cell 
replication, hence p16 negativity showing cor-
relation with ER negativity, PR negativity, and 
higher Ki67 LI that are related with breast can-
cer aggressiveness can be explained. 
Figure 1. Immunohistochemical expression of p16 and pRB according to the molecular subtype. p16 negativity rate 
is higher in TNBC and high rate of p16 expression is observed in luminal B and HER-2. p16 alteration is higher in 
luminal B and HER-2 groups, and pRB expression is higher in HER-2 group and lower in luminal B group.
Table 4. Expression of metabolism-related proteins according to breast cancer subtype
Parameter Total (n = 406) (%)
Luminal A
(n = 168) (%)
Luminal B
(n = 87) (%)
HER-2
(n = 32) (%)
TNBC
(n = 119) (%) P-value
p16/pRB status < 0.001
    p16(+)/pRB(+) 64 (100.0) 12 (18.8) 24 (37.5) 11 (17.2) 17 (26.6)
    p16(+)/pRB(-) 311 (100.0) 153 (49.2) 54 (17.4) 20 (6.4) 84 (27.0)
    p16(-)/pRB(+) 3 (100.0) 0 (0.0) 1 (33.3) 0 (0.0) 2 (66.7)
    p16(-)/pRB(-) 28 (100.0) 3 (10.7) 8 (28.6) 1 (3.6) 16 (57.1)
Altered p16/pRB status < 0.001
    Altered p16/pRB(+) 31 (100.0) 4 (12.9) 12 (38.7) 5 (16.1) 10 (32.3)
    Altered p16/pRB(-) 163 (100.0) 62 (38.0) 38 (23.3) 9 (5.5) 54 (33.1)
    Non-altered p16/pRB(+) 36 (100.0) 8 (22.2) 13 (36.1) 6 (16.7) 9 (25.0)
    Non-altered p16/pRB(-) 176 (100.0) 94 (53.4) 24 (13.6) 12 (6.8) 46 (26.1)
TNBC, triple negative breast cancer.
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The previous study has reported that p16 does 
not have any impact on clinicopathologic fac-
tors of breast cancer [10], but this discrepancy 
can be explained by the type of antibody used 
and the difference in criteria for interpretation. 
Moreover, as altered p16/pRB(+) type is expect-
Table 5. Correlation between clinicopathologic factors and p16/pRB status
Parameters
p16 alteration p16 status pRB status
No 
n = 212 (%)
Yes 
n = 194 (%) p-value
Negative
n = 31 (%)
Positive
n = 375 (%) p-value
Negative
n = 339 (%)
Positive
n = 67 (%) p-value
Age (years) 0.359 0.576 0.452
    ≤ 50 115 (54.2) 114 (58.8) 16 (51.6) 213 (56.8) 194 (57.2) 35 (52.2)
    > 50 97 (45.8) 80 (41.2) 15 (48.4) 162 (43.2) 145 (42.8) 32 (47.8)
Histologic grade 0.449 0.204 0.108
    I/II 142 (67.0) 123 (63.4) 17 (54.8) 248 (66.1) 227 (67.0) 38 (56.7)
    III 70 (33.0) 71 (36.6) 14 (45.2) 127 (33.9) 112 (33.0) 29 (43.3)
Tumor stage 0.427 0.093 0.894
    T1 110 (51.9) 93 (47.9) 11 (35.5) 192 (51.2) 170 (50.1) 33 (49.3)
    T2/T3 102 (48.1) 101 (52.1) 20 (64.5) 183 (48.8) 169 (49.9) 34 (50.7)
Nodal metastasis 0.925 0.422 0.944
    Absent 131 (61.8) 119 (61.3) 17 (54.8) 233 (62.1) 209 (61.7) 41 (61.2)
    Present 81 (38.2) 75 (38.7) 14 (45.2) 142 (37.9) 130 (38.3) 26 (38.8)
ER status 0.187 0.002 0.242
    Negative 75 (35.4) 81 (41.8) 20 (64.5) 136 (36.3) 126 (37.2) 30 (44.8)
    Positive 137 (64.6) 113 (58.2) 11 (35.5) 239 (63.7) 213 (62.8) 37 (55.2)
PR status 0.237 0.004 0.009
    Negative 99 (46.7) 102 (52.6) 23 (74.2) 178 (47.5) 158 (46.6) 43 (64.2)
    Positive 113 (53.3) 92 (47.4) 8 (25.8) 197 (52.5) 181 (53.4) 24 (35.8)
HER-2 status 0.418 0.895 0.001
    Negative 176 (83.0) 155 (79.9) 25 (80.6) 306 (81.6) 286 (84.4) 45 (67.2)
    Positive 36 (17.0) 39 (20.1) 6 (19.4) 69 (18.4) 53 (15.6) 22 (32.8)
Ki-67 LI (%) 0.013 < 0.001 < 0.001
    ≤ 14 132 (62.3) 97 (50.0) 8 (25.8) 221 (58.9) 207 (61.1) 22 (32.8)
    > 14 80 (37.7) 97 (50.0) 23 (74.2) 154 (41.1) 132 (38.9) 45 (67.2)
Figure 2. Corre-
lation between 
combined p16/
pRB status and 
clinicopatholog-
ic factors.
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ed to be most aggressive in the aspect of tu- 
mor cell proliferation, our results demonstrat-
ing higher HER-2 positivity and higher Ki67 LI in 
the subtype correspond to the expectation. 
P16 and pRB were differentially expressed 
according to the molecular subtypes; p16 nega-
tivity was highest in the TNBC and high p16 
expression was observed in luminal B and 
HER-2 types. P16 alteration was higher in lumi-
nal B and HER-2 types, and pRB expression 
was high in HER-2 type and low in luminal A 
type. These results cannot be compared with 
the results of the previous study since the latter 
did not include assessment of molecular sub-
types. However, cases of altered expression 
of p16 and/or pRB showed correlation with 
aggressive parameters, and such results seem 
to concord with the results of the previous 
study [10, 11, 13]. 
In conclusion, the status of p16 and pRB altera-
tion is different in each of the molecular sub-
types of breast cancer, and the rate of abnor-
mal expression is higher in HER-2 type. 
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